MLD to Present Plasmalogen Therapy at Society for Neuroscience

MLD is pleased to announce that their abstract entitled “Development of oral plasmalogen precursors for the treatment of Alzheimer’s disease: Clinical proof-of-concept in the pediatric orphan disease Rhizomelic chondrodysplasia punctata” has been accepted and will be presented at Neuroscience 2018 on Saturday November 3rd. Dr. Tara Smith, Vice President Therapeutics, will be attending the conference and is looking forward to meeting potential partners or collaborators.